Gujarat Themis Biosyn Ltd

Guj. Themis Bio. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gujarat Themis Biosyn Ltd

₹ 413 3.29%
24 Apr 12:42 p.m.
gtbl.in BSE: 506879
About

Incorporated in 1981, Gujarat Themis Biosyn
Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]

Key Points

Business Overview[1][2]
Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and became India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin.

Website BSE
  • Market Cap ₹ 3,000 Cr.
  • Current Price ₹ 413
  • High / Low ₹ 423 / 145
  • Stock P/E 54.6
  • Book Value ₹ 24.5
  • Dividend Yield 0.26 %
  • ROCE 61.1 %
  • ROE 45.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 71.8% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 49.0%
  • Debtor days have improved from 61.0 to 43.9 days.
  • Company's working capital requirements have reduced from 114 days to 89.8 days

Cons

  • Stock is trading at 16.6 times its book value
  • Promoter holding has decreased over last 3 years: -4.13%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
24 23 32 35 19 29 45 48 28 28 50 40 39
14 15 16 17 9 16 22 23 16 13 26 23 21
Operating Profit 11 8 17 18 10 13 23 24 12 15 24 17 18
OPM % 44% 36% 52% 53% 53% 45% 51% 51% 43% 53% 47% 42% 46%
1 1 1 1 1 2 1 1 2 1 1 1 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 11 8 17 18 10 14 24 25 13 16 24 17 18
Tax % 31% 29% 25% 25% 26% 29% 25% 26% 26% 25% 26% 26% 26%
7 6 13 14 7 10 18 19 10 12 18 13 13
EPS in Rs 1.03 0.80 1.78 1.90 0.98 1.35 2.45 2.58 1.35 1.61 2.44 1.73 1.79
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
9 28 30 31 33 36 39 41 85 91 115 149 156
11 25 24 25 27 30 33 34 53 50 57 75 83
Operating Profit -2 3 6 7 6 6 6 7 32 40 58 74 73
OPM % -26% 11% 21% 21% 19% 17% 16% 18% 37% 45% 51% 50% 47%
6 0 0 -0 0 0 0 2 2 3 4 6 4
Interest 1 1 1 0 0 0 0 0 1 1 1 0 0
Depreciation 1 1 1 1 1 1 1 1 1 2 2 3 3
Profit before tax 2 1 5 5 5 5 5 8 31 41 59 77 74
Tax % 0% 0% 0% 0% 0% 10% 20% 22% 24% 26% 26% 25%
2 1 5 5 5 4 4 6 24 30 44 58 55
EPS in Rs 0.27 0.15 0.62 0.63 0.64 0.60 0.53 0.88 3.26 4.16 6.01 7.98 7.57
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 10% 0% 37% 14%
Compounded Sales Growth
10 Years: 18%
5 Years: 31%
3 Years: 21%
TTM: 4%
Compounded Profit Growth
10 Years: 50%
5 Years: 72%
3 Years: 36%
TTM: -2%
Stock Price CAGR
10 Years: 70%
5 Years: 120%
3 Years: 103%
1 Year: 168%
Return on Equity
10 Years: %
5 Years: 51%
3 Years: 49%
Last Year: 46%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 12 7 7 7 7 7 7 7 7 7 7 7 7
Reserves -25 -17 -13 -8 -3 1 5 11 35 63 96 142 171
11 11 9 6 3 4 1 6 8 5 1 0 2
20 17 13 9 8 9 8 8 14 14 18 17 17
Total Liabilities 17 18 16 15 15 21 20 33 64 88 122 166 197
11 12 11 10 9 11 11 15 17 19 19 33 37
CWIP 1 0 0 0 0 0 0 1 0 2 13 21 58
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
6 6 5 5 5 11 10 17 47 67 90 113 102
Total Assets 17 18 16 15 15 21 20 33 64 88 122 166 197

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
2 0 4 3 4 3 6 1 1 11 40 40
-4 -3 -0 -0 -1 -3 -1 -6 -3 -2 -30 -20
2 2 -3 -3 -3 -0 -4 5 2 -5 -14 -13
Net Cash Flow 0 -0 1 -1 -0 0 1 0 -0 3 -4 6

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 109 37 15 28 24 71 26 52 87 59 80 44
Inventory Days 88 58 78 194 144 255 201
Days Payable 737 1,498 947 240 84 145 131
Cash Conversion Cycle -540 -1,403 15 28 24 71 -844 52 41 119 189 114
Working Capital Days -681 -172 -128 -76 -69 -30 -43 -58 42 96 158 90
ROCE % 208% 121% 81% 55% 42% 45% 84% 67% 67% 61%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
74.99% 74.99% 74.99% 74.99% 74.99% 75.00% 75.00% 75.00% 75.00% 75.00% 70.87% 70.87%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.86% 1.05%
0.03% 0.03% 0.31% 0.31% 0.31% 0.03% 0.03% 0.03% 0.03% 0.03% 0.04% 0.82%
24.97% 24.97% 24.70% 24.70% 24.69% 24.98% 24.96% 24.95% 24.95% 24.96% 28.23% 27.26%
No. of Shareholders 10,15812,93013,05913,91713,83014,90416,55016,80417,37319,84628,65529,576

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls